Biotech Vertex Pharmaceuticals stock tumbled on news of disappointing drug data. CEO Reshma Kewalramani paid nearly $4 ...

The heritage British brand has been revived by a chairman whose impressive career before watchmaking includes a three-year ...

Vertex Pharmaceuticals' unchanged guidance and disappointing trial outcomes for its investigative pain relief treatment led ...

Vertex Pharmaceuticals' Seaport headquarters buildings have been refinanced for $1 billion, putting a ten-figure value on an ...

Vertex Pharmaceuticals Incorporated's stock drop is overblown. With strong CF revenue, pipeline potential, & insider ...

A federal judge ruled Hampton’s Zoning Board had ample evidence to reject the tower, but left one legal claim standing.

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

Vertex Pharmaceuticals will stop developing its experimental non-opioid painkiller as a solo treatment after a mid-stage ...

Vertex Pharmaceuticals beat Wall Street estimates for quarterly results on Monday, helped by demand for its new cystic ...

Shares of Vertex Pharmaceuticals sank 15% after the drugmaker announced a study showed its experimental pain medicine was not ...

The experimental drug is similar to the Boston-based company’s recently approved pill Journavx but could potentially be given ...

Vertex Pharmaceuticals Inc. fell after an experimental pain drug failed to provide post-surgery benefits and US regulators ...